Literature DB >> 1583339

Lack of activity of amphotericin B in systemic murine fusarial infection.

E J Anaissie1, R Hachem, C Legrand, P Legenne, P Nelson, G P Bodey.   

Abstract

Systemic fusarial infections have emerged as a significant cause of mortality in cancer patients. Yet, little is known about the management of these infections. The in vivo antifungal activity of amphotericin B in CF1 mice with disseminated fusarial infections was studied. Two pathogenic strains of Fusarium solani were used. Intraperitoneal administration of amphotericin B in daily doses of 0.5, 1, and 2 mg/kg for less than or equal to 10 days did not prolong survival of treated animals. Clearance of F. solani from kidneys was similar in mice treated with 1 mg/kg per day of amphotericin B and in untreated animals. These results are in agreement with the known in vitro and in vivo resistance of Fusarium species to amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583339

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  In vitro and in vivo experimental activities of antifungal agents against Fusarium solani.

Authors:  J Guarro; I Pujol; E Mayayo
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis.

Authors:  Michail S Lionakis; Georgios Chamilos; Russell E Lewis; Nathan P Wiederhold; Issam I Raad; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 5.  Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.

Authors:  Herman A Carneiro; Jeffrey J Coleman; Alejandro Restrepo; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

6.  Treatment of murine fusariosis with SCH 56592.

Authors:  M Lozano-Chiu; S Arikan; V L Paetznick; E J Anaissie; D Loebenberg; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Pentamidine is active in vitro against Fusarium species.

Authors:  Michail S Lionakis; Russell E Lewis; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Recurrence of Fusarium solani abscess formation in an otherwise healthy patient.

Authors:  H S Leu; A Y Lee; T T Kuo
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 9.  Fusarium infections in immunocompromised patients: case reports and literature review.

Authors:  M Rabodonirina; M A Piens; M F Monier; E Guého; D Fière; M Mojon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

Review 10.  Taxonomy, biology, and clinical aspects of Fusarium species.

Authors:  P E Nelson; M C Dignani; E J Anaissie
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.